What does this research mean for the field?

A systematic mapping of available evidence is necessary to determine the efficacy, safety profile, and therapeutic persistence of neurokinin receptor antagonists for managing vasomotor symptoms in breast cancer survivors. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review aims to evaluate the effectiveness and safety of neurokinin receptor antagonists for managing vasomotor symptoms in breast cancer survivors.

April 24, 2026Open Access

Efficacy and Safety of Neurokinin Receptor Antagonists for Vasomotor Symptoms in Breast Cancer: A JBI Scoping Review

Key Points

This review aims to evaluate the effectiveness and safety of neurokinin receptor antagonists for managing vasomotor symptoms in breast cancer survivors.
Conducted a scoping review following JBI guidelines and PRISMA-ScR protocol.
Mapped evidence regarding the efficacy, safety, and therapeutic persistence of specific antagonists like fezolinetant and elinzanetant.
Confirmed the existence of evidence supporting the efficacy of neurokinin receptor antagonists for vasomotor symptoms.
Highlighted safety profiles and potential therapeutic persistence of these medications in breast cancer survivors.

Abstract

This scoping review aims to map the available evidence on the efficacy, safety profile, and therapeutic persistence of neurokinin receptor antagonists (such as fezolinetant and elinzanetant) in the management of vasomotor symptoms specifically in breast cancer survivors. The study follows the Joanna Briggs Institute (JBI) guidelines and the PRISMA-ScR protocol.

Efficacy and Safety of Neurokinin Receptor Antagonists for Vasomotor Symptoms in Breast Cancer: A JBI Scoping Review

Key Points

Abstract

Cite This Study